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Prevalence
PCOS is one of the commonest endocrinopathies in women, 
affecting 5–10% of women in the reproductive age worldwide.9 The 
prevalence tends to vary depending on ethnicity and the criteria used 
to define PCOS. In the United States, prevalence rates of 5–10% 
have been quoted. PCOS also appears to be commoner in Mexican-
American than White or African-American women.10 It has also been 
reported that prevalence rates are higher in those with gestational 
diabetes,11 those who have premature adrenarche12 and in those 
with first-degree relatives who have PCOS.13 Prevalence data for 
PCOS in South Africans are not available.
Diagnosis
PCOS is in essence a diagnosis of exclusion once other ovulatory and 
androgen-excess disorders have been ruled out (Table I).
Late onset 21 hydroxylase deficiency, androgen secreting neoplasms, 
drug induced hyperandrogenism and Cushing’s syndrome at most 
account for 10% of women with androgen excess.14,15 Ovulatory 
disorders need to be considered especially when chronic anovulation 
occurs (with PCOM) and overt androgen excess is absent. The WHO 
has divided anovulation into 4 categories:
Introduction
The description of polycystic ovaries dates back as far as 17211 but it was Stein and Leventhal who first reported the disorder, that we now 
know as the polycystic ovary (or ovarian) syndrome (PCOS), in seven women with amenorrhoea, enlarged ovaries with multiple cysts and 
hirsutism.2 These patients were treated with ovarian wedge resection and of the seven all had return of their menstrual cycles, and two 
conceived. With the advent of hormonal assays in the late 1960’s and early 1970’s, the diagnostic focus expanded to include endocrine 
abnormalities in the hypothalamic-pituitary-gonadal (HPG) axis.3 Elevated luteinising hormone (LH) levels and hyperandrogenaemia were 
therefore added to the diagnostic criteria for PCOS.4 The advent of pelvic ultrasonography in the late 1970’s allowed for the non-invasive 
detection of polycystic ovarian morphology. However, this tool confounded matters when it was discovered that polycystic ovaries was a 
“common finding in normal women”,5 and that it also occurred in diverse endocrine disorders such as hypothyroidism, hyperprolactinaemia, 
congenital adrenal hyperplasia and hypothalamic amenorrhoea.6 The finding of polycystic ovaries in normal women has been variably 
referred to as polycystic ovarian disease (PCOD), polycystic ovaries (PCO) and polycystic ovarian morphology (PCOM). We prefer the to use 
the term PCOM in this setting as it simply describes the ultrasound appearance of the ovaries without any syndromic connotations. Despite 
the strong link between diabetes mellitus and PCOS, it was only in 1980 when Burghen and coworkers first described hyperinsulinaemia and 
insulin resistance in PCOS.7 This has subsequently been confirmed by many others. 
The identification of PCOS now encompasses a heterogeneous presentation but has at its core three principal features: 8 
i. Hyperandrogenism
ii. Anovulation, and/or
iii. Polycystic ovarian morphology (PCOM) on ultrasonography
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Table I: Disorders that can mimic PCOS
Androgen-excess disorders that can mimic PCOS
1.  Late onset non-classic 21 hydroxylase deficiency
2.  Idiopathic hirsutism
3.  Syndromes of severe insulin resistance e.g. HAIR-AN syndrome
4.  Ovarian androgen-secreting tumours
5.  Use of anabolic or androgenic drugs
6.  Cushing’s syndrome
Ovulatory disorders that mimic PCOS
1.  Hypothalamic and pituitary disorders causing amenorrhoea
2.  Premature ovarian failure
Other disorders
1.  Thyroid dysfunction
2.  Hyperprolactinaemia
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Class 1: Hypogonadotrophic hypogonadal anovulation
This accounts for about 10% of ovulatory disorders. Women have 
low to low normal FSH concentrations with low serum oestradiol 
concentrations due to decreased GnRH or pituitary unresponsiveness 
to GnRH.
Class 2: Normogonadotrophic normooestrogenic anovulation
This group accounts for 85% of ovulatory disorders. Women may 
secrete normal gonadotrophins and oestrogens but FSH secretion 
during the follicular phase is subnormal. This subgroup includes 
women with PCOS.
Class 3: Hypergonadotrophic hypogonadism
This is the smallest group (5% of ovulatory disorders). The primary 
causes are premature ovarian failure and ovarian resistance.
Hyperprolactinaemic anovulation
Increased prolactin levels inhibit gonadotrophins and oestrogen 
secretion. These patients may have regular anovulatory cycles or 
oligo/amenorrhoea. Their serum gonadotrophins are usually normal.
Hypothalamic amenorrhoea or functional amenorrhoea (HA), which 
falls into group 1, accounts for up to 48%16 of secondary amenorrhoea 
and is often related to metabolic, psychological or physical stressors 
or weight loss related to limited caloric intake or excessive physical 
exercise. It is a diagnosis of exclusion, much like PCOS. Typically 
they do not bleed following withdrawal of progesterone therapy as 
they do not produce enough oestrogen (unlike PCOS). PCOM may 
be seen in this entity17 although recent texts have characterised the 
ovaries as more multifollicular than polycystic and the increased 
stromal area typical in PCOM is not present,18 The diagnosis can be 
problematic as both PCOS and HA are diagnoses of exclusion and 
the decision to which takes precedence over the other is unresolved. 
The cause is thought to be a disrupted GnRH pulse frequency and 
amplitude secondary to the underlying stressors or diseases which 
cause anovulation. The aetiology of the PCOM is not thought to be 
extra ovarian but rather increased endogenous ovarian androgen 
synthesis.18
Rarely pituitary or hypothalamic disease may cause hypogonadotrophic 
hypogonadism resulting in anovulation although features of androgen 
excess or PCOM may be absent in these instances.
Premature ovarian failure (POF) is diagnosed if ovarian failure occurs 
before the age of 40 in the absence of any demonstrable genetic 
abnormality. It is characterised by elevated gonadotrophins with 
decreased oestrogen concentration and amenorrhoea. The exact 
cause has not been defined but it is linked to other autoimmune 
disorders and may be part of the polyendocrine syndrome. 
Antibodies to gonadotrophins and gonadotrophin receptors have 
been found but mutations in the LH and FSH receptors have also 
been documented. Other known causes are genetic aberrations 
involving the X chromosome and iatrogenic causes e.g. following 
surgery, chemotherapy etc.19 PCOS and POF both can present with 
oligo/anovulation and POF thus needs to be excluded in the workup 
of such a patient. The controversy, as will be discussed below, is 
whether these ovulatory disorders should be considered to be similar 
in presentation to PCOS in the absence of androgen excess (despite 
the presence of ovulatory dysfunction or PCOM). 
Controversies regarding diagnostic criteria for PCOS
There have been three different sets of criteria set forth by different 
bodies8,20,21 and all have met with some degree of controversy. 22-24 
The first arose via an NIH expert conference in 1990.20 This set of 
criteria requires all of the following to fulfill the diagnosis of PCOS:
i. Presence of anovulation, plus
ii. Clinical and / or biochemical evidence of hyperandrogenism, and
iii. Exclusion of other related disorders e.g. hyperprolactinaemia, 
thyroid disease, congenital adrenal hyperplasia (CAH) etc.
The presence of polycystic ovaries on ultrasound was considered 
suggestive but not diagnostic in this set of criteria as it was thought 
to have low specificity (25% of normal women can have PCOM and 
up to 25% of women with the syndrome may not have PCOM).8,25-27
Using the NIH definition it was thus possible to isolate 3 clinical 
phenotypes of PCOS:
Group 1: Clinical hyperandrogenism (hirsutism), biochemical 
hyperandrogenism and anovulation
Group 2: Biochemical hyperandrogenism and anovulation
Group 3: Clinical hyperandrogenism (hirsutism) and anovulation
Interestingly in a US cohort of patients, the Group 1 phenotype 
occurred most commonly, followed by Group 2 and 3 (50%, 30% 
and 20% respectively). Group 1 also had the highest fasting insulin 
levels and Group 3 had the lowest.28
In May 2003 another expert conference was hosted in Rotterdam 
sponsored by European Society for Human Reproduction and 
Embryology and the American Society for Reproductive Medicine.8 
The diagnostic criteria that emerged from this conference were the 
presence of two or more of the following:
i. Oligo- or anovulation
ii. Clinical (hirsutism, acne or androgenic alopecia) and/or 
biochemical evidence of androgen excess
iii. Polycystic ovaries
It also required the exclusion of other related disorders.
By expanding the NIH criteria, the Rotterdam criteria now identified 
2 additional phenotypes of PCOS (Figure 1) viz.
•	 Women	with	demonstrable	polycystic	ovaries	(PCOM)	with	clinical	
and/or biochemical androgen excess but no anovulation
•	 Women	with	PCOM	and	anovulatory	 cycles	but	 no	evidence	of	
androgen excess
Disagreement has persisted regarding whether these two additional 
phenotypes (Figure 1, areas 2 and 3) actually do have classical 
PCOS, or whether they actually represent a milder form-fruste of 
PCOS. Subsequent studies have demonstrated that these women 
with PCOM but without overt hyperandrogenism (whether ovulatory 
or not), are either similar to control women without PCOM or have 
significantly fewer metabolic features than PCOM women who are 
also hyperandrogenaemic. These women may have slightly higher 
(albeit within the normal range) androgen, fasting insulin and LH 
levels, and lower SHBG levels. Therefore they probably form part of 
the spectrum of PCOS disorders but the significance of these findings 
on future metabolic risk and fertility remains to be determined.28-30 
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The Rotterdam criteria also make it difficult to differentiate between 
patients with PCOM and hypothalamic-pituitary amenorrhoea from 
non-obese women with PCOS. In addition, only women who fulfill 
the NIH criteria have been shown to be at high risk for some of the 
complications associated with PCOS e.g. the metabolic syndrome.31
Another criticism of the Rotterdam criteria was that it has significant 
implications for research as it expanded the already heterogeneous 
nature of this population of patients. In addition it makes 
ultrasonography essential, and significantly increases the population 
of patients (by 50%) now characterised as having PCOS.32 This has 
severe economic implications in light of the long term monitoring 
required for this condition.
In 2006, the Androgen Excess Society (AES) recommended an 
evidence-based definition for PCOS. This set of criteria highlighted 
PCOS as primarily an androgen-excess disorder and proposed that 
PCOS be diagnosed by all of the following:
i. Androgen excess (clinical or biochemical)
ii. Ovarian dysfunction (anovulation/oligo-ovulation and/or polycystic 
ovaries)
iii. Exclusion of other androgen-excess and ovulatory disorders21,33
This definition was an expansion of the NIH one and added only 
one additional phenotype viz. PCOM with hyperandrogenism and 
apparently normal ovulation. These patients have been characterised 
as having “mild PCOS” with only marginal increases in LH, some 
markers for cardiovascular disease and marginal elevations in 
insulin.34-37 Long-term studies are required to determine the 
reproductive and metabolic consequences of this group. It should be 
noted that the task force did not exclude the possibility that a subset 
of women with PCOM and anovulation and no androgen excess may 
exist but decided to defer expanding the definition until long-term 
outcomes in this subgroup become available.
In essence the 1990 NIH and the 2006 AES definitions encompass 
patients at higher risk for infertility and metabolic syndrome than the 
general population, whereas the Rotterdam criteria define a larger 
more heterogeneous group of women, but whose risk for infertility 
and metabolic syndrome is lower. 
It is noteworthy that all three sets of diagnostic criteria did not include 
obesity, measurements of insulin resistance (IR) or hyperinsulinaemia, 
or elevated luetenising hormone (LH) levels. These latter features are 
present only in approximately 50% of PCOS patients.8
A clinical approach to the diagnosis of PCOS
1.  Assessment of ovulatory dysfunction
Approximately 75% of women with PCOS have menstrual irregularities 
suggestive of anovulation. This includes oligomennorhoea (defined 
as less than 8 menstrual cycles per year, or cycles that are longer 
than 35 days) and amenorrhoea (the absence of menstrual cycles for 
> 3 months without pregnancy). However 20–30% of oligoanovulatory 
women with PCOS can present with apparent eumenorrhoea 
(i.e. subclinical oligoanovulation). Therefore eumenorrhoeic women 
with other features of PCOS should have multiple determinations of 
serum progesterone (drawn between Day 20–24 of their menstrual 
cycle) to accurately categorise their ovulatory status.21
2.  Assessment of clinical hyperandrogenism
Hirsutism is the commonest clinical manifestation of androgen 
excess in PCOS. Overall 60–75% of patients with PCOS will have 
hirsutism38 but there is wide variation based on ethnicity and degree 
of obesity. Its assessment should therefore be ethnic specific. Most 
studies have examined Caucasian and African-American women 
where mean Ferriman Gallwey scores in excess of 5–8 have been 
considered abnormal.39 East Asian women have a lower prevalence 
of hirsutism40 while the prevalence and severity of hirsutism in 
women with PCOS of Southern Asian origin (Bengali, Gujerati, 
or Dravidian Indian) is greater when compared to Caucasians.41 
In the latter study this was found to be correlated with greater insulin 
resistance (as manifested by higher fasting insulin levels and lower 
insulin sensitivity). The differences in the presence and degree of 
hirsutism are potentially the result of differences in the sensitivity of 
the pilosebaceous unit to circulating androgens.42 The subjectivity in 
the assessment of hirsutism is confounded further by the fact that 
there are no normative data for different populations. In addition the 
evaluation system is subjective and most patients will have depilated 
before presentation thus making scoring difficult. 
Other clinical features of hyperandrogenism are acne in younger 
women and female-pattern alopecia (thinning at the crown with 
preservation of the anterior hairline) in older women although, in 
general, these signs are considered to be less reliable markers of 
hyperandrogenism. As with hirsutism, there are ethnic differences in 
the prevalence of acne (also higher in Asian-Indians).41
The prevalence of PCOS in women with hirsutism is 75–80%, 
whereas 20–40% with acne alone have PCOS. About 10% of women 
with alopecia only will have PCOS.33,43-45
3.  Assessment of biochemical hyperandrogenism 
About 70% of patients with PCOS diagnosed by NIH criteria will 
have elevated serum free testosterone levels. Measurement of 
free testosterone using radioimmunoassay is inaccurate and using 
a direct method of measurement such as equilibrium-dialysis can 
be expensive and complex. Most experts recommend measuring 
serum total testosterone and sex hormone binding globulin (SHBG) 






Figure 1: Core features of PCOS
This diagram illustrates that each of the 3 core components of PCOS 
may occur in isolation or combinations outside the context of PCOS.  
Area 1 represents subjects fulfilling the 1990 NIH criteria for PCOS. 
The 2003 Rotterdam criteria adds subjects in areas 2 and 3
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free androgen index (Testosterone/SHBG x 100) or, the mass action 
equation.
Most total testosterone assays are geared more towards measuring 
male range (higher) values and are complicated by age and 
reproductive stage (total testosterone levels tend to decrease as 
menopause approaches and then remain elevated in older age). 
Total testosterone levels are also dependent on SHBG levels, which 
are often low in PCOS women and elevated in women taking the 
contraceptive pill. Moreover, many manufacturers do not have 
accurate normative data for females. Thus the measurement of total 
testosterone alone is of little value in PCOS. 
The measurement of androstenedione may detect an additional 
10% of hyperandrogenaemic women and is not recommended 
routinely at this time. It may have utility in the patient suspected of 
having hyperandrogenaemia when the free testosterone is normal. 
Dehydroepiandrosterone measurements also have limited clinical 
use as it has significant diurnal and inter-individual variation and can 
be elevated by any degree of stress. Measurements of its sulphated 
metabolite (DHEA-S) are preferred. Elevated DHEA-S levels are 
found in 25-35% of women with PCOS, and it is the sole biochemical 
androgen abnormality in approximately 10%. Very high levels of 
DHEA-S may be a marker of adrenocortical disorders, but DHEA-S 
levels do not always reflect adrenal steroidogenesis.33
4.  Assessment for polycystic ovarian morphology (PCOM)
Ovarian morphology is assessed preferably by trans-vaginal 
ultrasound (TVUS) as the definition of PCOM has been revised on 
the basis of this technique. The Rotterdam definition of polycystic 
ovaries uses the criteria set forth by Dewailley et al.46 PCOM can be 
established in the follicular phase when at least one ovary has ≥ 12 
follicles measuring 2–9 mm in diameter and/or the ovarian volume 
is > 10 cm³ in at least one ovary. Subsequent studies have shown 
the threshold for ovarian volume can be reduced to >7.5 cm³. The 
follicles are usually tightly spaced along the periphery of the ovary 
with increased stromal volume (the “pearl necklace” sign). However 
the previous measurement of stromal volume (which previously was 
regarded as being specific for PCOM) has been replaced by ovarian 
volume as a good surrogate.8 
Adolescent girls can be evaluated using transabdominal ultrasound 
with assessment of ovarian volume only, as accurate determination 
follicle number is less reliable via this route.47 A transabdominal 
ultrasound will also in most cases exclude an ovarian or uterine 
abnormality. The ovarian volume is the parameter of greatest 
importance. The transabdominal criteria for a polycystic ovary 
as defined by Adams et al48 is where, in one plane 10 follicles 
are identified (usually between 2–8 mm in diameter) arranged 
peripherally around a dense core of stroma or increased amount 
of stroma. Transvaginal ultrasound has superceded transabdominal 
ultrasound due to greater resolution especially in obese patients. 
However a study done in women having repeated scans for PCOS 
found that up to 20% of women refused a transvaginal scan.49 The 
new cut off for the ovarian volume was as a result of reports that 
showed a greater ovarian volume in patients with PCOS. The cut off 
of ≥ 12 follicles throughout the ovary instead of a single plane was 
based on a report showing 99% specificity and 75% sensitivity for 
this value in differentiating between PCOS and normal individuals.46 
Recently a surrogate measure of follicle pattern known as stroma-
total area ratio was shown to have a 100% sensitivity and specificity 
for polycystic ovaries.50
The ultrasonographic definition of PCOM does not apply to women 
on the oral contraceptive pill as it can alter the ovarian appearance. 
Patients need to be counselled to discontinue the pill for 8 weeks 
before scanning is undertaken.33
The term polycystic ovary to describe this morphology is a misnomer 
because there are no dominant cysts or follicles larger than 10 mm 
because of anovulation. If there is a follicle that is > 10 mm, the 
scan will need to be repeated in the following cycle. A study from 
Cape Town demonstrated no correlation between the severity of 
ovarian morphology and the endocrine or metabolic manifestations 
of PCOS.57 
Newer modalities like 3-D ultrasound and MRI have been explored 
and while good correlation between 3-D and 2-D measurements 
were found, 3-D is more expensive and requires more training.47,52 
The cost of MRI imaging limits its use despite reported good 
sensitivity.
As noted previously, PCOS is a functional disorder that does not 
depend on the presence of polycystic ovaries, and the absence 
of PCOM does not exclude the diagnosis. Approximately 20–30% 
of asymptomatic women < 35 years of age will have PCOM; it is 
estimated that about 20% of these women will actually have PCOS 
by NIH definition; the other associations with PCOM are listed in 
Table II. Conversely, 10–25% of patients with PCOS by NIH definition 
will not have PCOM on ultrasonography.8,21,33,38
As mentioned previously, up to 30% of females with normal 
androgens and normal menses can have PCOM.47,53 It has also been 
suggested that some women with PCOM and normal ovulatory cycles 
may have higher LH, androgen and insulin levels as well as lower 
SHBG levels (albeit in the normal range) when compared with control 
women without PCOM.54 This phenotype may therefore represent the 
mildest form of PCOS. 
In pre and peri-pubertal females, histological studies have revealed 
features similar to PCOM. There is increased volume, a multifollicular 
rather than multicystic appearance, hyperplasia with luteinisation, 
atretic follicles and cortical fibrosis. This is predominantly due to the 
fact that this is a period where a high follicular turnover does not exist 
and is a transitional period typical of early pubertal development.55
Table II: Circumstances and conditions associated with polycystic ovarian 
morphology*
i.  Up to 30% of females with normal menses and normal androgens
ii.  Normal pre-pubertal children
iii.  Normal girls in the first few years following puberty
iv.  Adrenal hyperplasia
v.  Long term use of oral contraceptives
vi.  Autoimmune oophoritis
vii. Periovarian adhesions
viii. Primary hypothyroidism
ix. Long term androgen use in female to male transsexuals
x. Hyperprolactinaemia
*Most of these are probably co-incidental.
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Studies in women with chronic use of oral contraceptives have also 
shown features suggestive of PCOM.56 The overall appearance may 
appear polycystic but the ovarian volume in these women may be 
decreased.57 It has been postulated that the use of contraceptives 
over a long period allows follicular development to continue but 
growth stops.
PCOM may also be seen with patients with tubo-ovarian inflammatory 
disease and peri ovarian adhesions.58 It has been suggested 
that these patients have greater numbers of atretic follicles and 
cystic corpora lutea possibly due to congestion of the ovary and 
interruption of the ovarian blood supply. The literature surrounding 
this is scanty. Autoimmune oophoritis has been documented to have 
PCOM as well.59 It is thought that the increased gonadotrophins, 
secondary to the ovarian pathology, are possibly responsible for the 
cystic changes.54 This morphology may also be seen in women with 
congenital adrenal hyperplasia and in those with hyperandrogenism 
in the absence of cyclical irregularity.34
5.  Differentiating PCOS from other androgen-excess and 
ovulatory disorders
Other common androgen excess disorders are: Cushing’s syndrome, 
androgen secreting tumours, non-classical congenital adrenal 
hyperplasia (NC-CAH), HAIR-AN (hyperandrogenism-insulin 
resistance-acanthosis nigricans) syndrome and drug-induced 
hyperandrogenism. These are mostly acquired disorders so there is 
usually a post-pubertal period of normal menstrual cycles without 
symptoms of hyperandrogenism. In contrast, PCOS often has an 
adolescent onset (not infrequently post-menarche) and affects most 
of the woman’s reproductive life.
Although Cushing’s syndrome can share many of the clinical features 
of PCOS (menstrual irregularities, acne and hirsutism as well as 
evidence of PCOM), other signs consistent with Cushing’s syndrome 
are usually evident. In view of the low prevalence of this disorder in 
patients with PCOS, a 24 hr urinary free cortisol can be measured only 
if the clinical examination warrants it. Serum cortisol measurements 
are notoriously unreliable in the presence of oral contraceptive use 
because of elevated cortisol binding globulin levels.
Androgen secreting tumours are usually ovarian in origin but 
occasionally arise from the adrenal glands. Clinically these patients 
have rapid onset of virilisation with clitoromegaly and breast atrophy, 
features which are rarely found in PCOS. In addition androgen levels 
are markedly elevated with elevations in both testosterone and 
DHEA-S levels.
21-hydroxylase deficient non-classic congenital adrenal hyperplasia 
occurs due to mutations in the CYP 21 gene resulting in 
abnormal 21-hydroxylase activity and a shift towards androgen 
overproduction. As with Cushing’s syndrome, many symptoms are 
shared with PCOS (hirsutism, oligo-anovulation, infertility, acne and 
hyperandrogenaemia). However symptoms tend to be milder and frank 
virilisation and hirsutism are rare. Screening for this disorder involves 
measurement of basal 17-hydroxyprogesterone levels in the morning 
during the follicular phase of the menstrual cycle (normal value is 
< 6 nmol/L). If the screening hydroxyprogesterone level is elevated, 
then a synacthen test is performed. 17-Hydroxyprogesterone levels 
> 45 nmol/L 60 min following intravenous synacthen is diagnostic 
of NC-CAH. Some carriers may have slightly raised values following 
the test but the levels are usually below 30 nmol/L. Screening for 
this condition is recommended especially in the high risk population 
group of Ashkenazi Jews and Europeans of Latin descent. 3-BHSD 
and 11β-hydroxylase deficient CAH are rare and routine screening 
is not recommended.
Other conditions that can present with hyperandrogenism and/or 
chronic anovulation are:
•	 Thyroid disease. Although it is uncommon to mistake the 
menstrual disturbance of thyroid disorders with PCOS, the 
disorder is common, screening is simple and inexpensive, and 
the disorder is easily treated. Thyroid function testing is therefore 
recommended. 
•	 Hyperprolactinaemia. Although one can find mild elevations of 
prolactin in 20–30% of women with PCOS (< 30 ng/ml), severe 
hyperprolactinaemia has been known to mimic PCOS.
•	 HAIR-AN Syndrome: About 3% of hyperandrogenic women suffer 
from this severe form of insulin resistance (IR) characterised 
by severe hyperandrogenism (and often virilisation) and severe 
acanthosis nigricans.33 The ovarian morphology is one of 
hyperthecosis, and ovarian/ovulatory dysfunction is common. 
The severe IR may be associated with lipodystrophy. Other forms 
of insulin resistance syndromes (types A and B) may also produce 
features similar to the HAIR-AN syndrome. As a result of the 
severe IR, progression to type 2 diabetes and the development 
of hypertension and dyslipidaemia with increased cardiovascular 
risk is common. Fasting insulin levels are usually in excess of 
80μU/ml and 2-hour post-glucose insulin levels are > 300μU/ml 
(unlike PCOS where fasting insulin levels are higher than obese 
control subjects without a diagnostic threshold). This is probably 
the only clinical indication for measuring insulin levels in the 
context of PCOS. 
Metabolic consequences of PCOS
1.  Obesity accompanies PCOS in 30–50% of patients in the 
US.61 This may exacerbate insulin resistance and metabolic 
abnormalities. Increased visceral adiposity is reflected by 
an increased waist circumference (> 88 cm) or waist to hip 
ratio. These are often associated with hyperandrogenism, IR, 
dyslipidaemia and glucose intolerance. Recent data suggests 
that although obesity increases the prevalence rates of PCOS to 
a modest degree, the metabolic consequences of obesity may 
precipitate a genetically susceptible individual to express the 
PCOS phenotype.62,63
2.  Insulin resistance is defined as a reduction in insulin-mediated 
glucose disposal and is measured (for research purposes) by the 
euglycaemic-hyperinsulinaemic clamp or a frequently-sampled 
glucose tolerance test. The prevalence of IR in the general 
population varies from 10–25% and 50% of women with PCOS 
(both obese and non-obese) have IR.2 Conversely and more 
importantly, although IR is more common among women with 
PCOS, 50% of women with PCOS do not have IR. Therefore the 
common prevailing belief among medical practitioners (personal 
observation) that IR is universally present and the “cause” of 
PCOS is a myth. 
 Some studies have found the prevalence of insulin resistance to 
be closer to 75%.64 The difference in prevalence rates in different 
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studies may be due to confounding factors like ethnicity. A study 
that compared South Asian and Caucasian patients in Leeds found 
higher fasting insulin and lower insulin sensitivity in the former 
group.41 In addition obesity may influence insulin sensitivity.59 
Hereditary risks like type 2 diabetes may also predispose to 
abnormal insulin sensitivity in these patients.66 Thus these factors 
may affect the prevalence data for a given population.
 Although there is a good correlation between calculated indices 
of IR (homeostatic model assessment or HOMA, and quantitative 
insulin sensitivity check index or QUICKI), these have been 
validated as epidemiological tools and there is no absolute cut-
off value that separates subjects with PCOS from control subjects. 
Moreover, there is currently no standardised insulin assay, there 
exists a large physiological fluctuation in intra-individual insulin 
levels, and insulin levels vary depending on the stage of pancreatic 
beta cell failure in those destined to develop glucose intolerance. 
It would also be irresponsible for laboratories to report on indices 
of IR without first establishing normal values from a control group 
in the population that they serve. The authors have no knowledge 
of these studies ever being conducted in South Africa.
 In any event, a biochemical measure of IR is not a criterion for the 
diagnosis of either the insulin resistance (metabolic) syndrome 
or PCOS. There is also no evidence that biochemical indices of 
IR (other than plasma glucose values derived from a GTT) offer 
any therapeutic or prognostic value in women with PCOS; neither 
does it predict weight loss (insulin resistant subjects with PCOS 
do not respond differently to weight loss interventions compared 
to PCOS subjects who are not IR).67 The assessment of IR is 
therefore a clinical one based on conventional criteria for the 
metabolic syndrome. The biochemical assessment of insulin 
levels and its derived indices currently has no merit in clinical 
practice and increases the cost of managing this condition 
unnecessarily. 
3. There are increased rates of impaired glucose tolerance (IGT) 
and diabetes mellitus in women with PCOS. The underlying 
abnormality is postulated to be insulin resistance. These women 
may often have normal fasting glucose and HbA1c levels but are 
glucose intolerant following a glucose challenge. By the fourth 
decade 31% of PCOS females have IGT and 7.5% have type 2 
diabetes.68 Overall, the risk of type 2 diabetes in PCOS women 
is increased 7-fold when compared to controls. This is obviously 
influenced by a family history of diabetes, obesity and age. The 
compensatory hyperinsulinaemia drives many of the phenotypic 
changes seen, including ovarian hyperandrogenism (elevated 
insulin drives ovarian theca cell androgen production) and 
acanthosis nigricans. 
 A 2 hr OGTT can be used to assess glucose tolerance in all 
patients with PCOS, although there are those that only advocate 
screening for diabetes if patients have additional risk factors 
for diabetes i.e. obesity, history of gestational diabetes, type 2 
diabetes in a first degree relative, high-risk ethnic origin.
 Insulin resistance is not a diagnostic criterion of this disorder 
and there is little to recommend insulin measurements outside 
research purposes. 
4. Increased cardiovascular risk has been postulated in patients 
with PCOS. Cardiovascular risk factors are increased including 
hyperlipidaemia, increased circulating androgens, insulin 
resistance and increased levels of inflammatory markers. 
Hypertriglyceridaemia, increased VLDL and LDL and decreased 
HDL are postulated to predispose to increased cardiovascular 
risk.69 There are also reports that increased coronary artery 
calcification and increased PAI-Type 1 may contribute to this 
risk.70 Endothelial function and vascular function is also altered in 
women with PCOS and vascular compliance has been reported to 
be decreased. There have also been suggestions that there is an 
increased rate of metabolic syndrome in these patients but it is 
unclear if this is secondary to the increased rates of obesity and 
its consequent metabolic complications. However all of these are 
surrogate markers and despite their presence, it remains to be 
proven (prospectively) that women with PCOS are at increased 
risk for cardiovascular-related morbidity and mortality. 
5. Obstetric and gynaecological: PCOS is the leading cause of 
anovulatory infertility and is an independent risk factor for 
the development of gestational diabetes, pregnancy induced 
hypertension, pre-eclampsia and increased fetal loss.71 
 The developmental competence of the oocyte is one of the early 
factors that affect embryonal development, establishment and 
maintenance of pregnancy and fetal development. Defects in 
glucose metabolism due to selective insulin resistance at the 
level of the ovaries could adversely affect the flow of glucose, 
pyruvate and purines in the oocyte leading to an altered meiosis 
and abnormal oocyte maturation.72 This could contribute to 
the anovulatory disturbances and increased early pregnancy 
loss associated with PCOS. In addition hyperinsulinaemia is 
postulated to decrease endometrial secretory proteins that play a 
role in implantation and maintenance of the pregnancy.73 High LH 
levels,74 elevated PAI-I levels induced by hyperinsulinaemia75 and 
obesity are some other explanations given for early pregnancy 
loss.76 The studies however have not been definitive and thus the 
evidence for a definite relationship remains weak.77-80
 A higher than expected risk of pre-eclampsia (PE) has been 
reported in a few studies.81,82 With regards to pregnancy induced 
hypertension (PIH), studies have found conflicting results. Some 
have found an increased incidence of PIH and PE,83,84 while others 
have found no relationship.85,86 Thus the relationship between 
hypertensive disorders of pregnancy and PCOS is not definite.
 The incidence of PCOS in women with gestational diabetes (GDM) 
is much higher than normal controls and this was true even when 
weight was accounted for.87,88 Thus patients with PCOS should be 
screened for GDM.
 Chronic anovulation can lead to unopposed endometrial 
stimulation by oestrogen and may lead to an increased risk 
of endometrial hyperplasia and a possibly increased risk of 
endometrial cancer.89,90 Thus one of the aims of therapy is to 
improve the frequency of ovulation and also improve fertility.
6.  Sleep apnoea: There is an increased prevalence of sleep apnoea 
noted that also appears to correlate with insulin resistance.91
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Theories of aetiology
The aetiology of PCOS is unknown92 but various theories have been 
put forth to explain the myriad of abnormalities encountered.
The pathophysiological focus has thus shifted from the ovary to the 
hypothalamic-pituitary-gonadal axis, to defects in insulin action 
(currently favoured by many) as the possible aetiological factor in 
PCOS. It is possible that all three processes may interact with varying 
degrees in each individual to create this heterogeneous disorder. 
Familial aggregation has been recognised99 but genetic analysis 
has not found a culprit candidate gene although many have been 
associated with PCOS. In addition environmental factors are thought 
to play a role as well.94 Animal studies have shown that exposure 
to androgens in pregnancy induces a PCOS-like syndrome and a 
similar effect in humans can only be postulated.101
The treatment of PCOS
Patients with PCOS will usually present to the practitioner with 
one or more dominant symptom of the disorder (obesity, hirsutism, 
acne, infertility, menstrual irregularity etc). It is important to choose 
therapies that are not only effective in addressing the patient’s most 
distressing symptom, but also attempt to improve the long-term 
outcomes of the disorder. 
1.  Lifestyle modification
Weight loss improves SHBG concentrations, decreases testosterone 
and improves menstrual function and conception rates. It has also 
been shown to improve insulin sensitivity. Weight loss of 2-5% has 
been associated with improved androgen levels, ovulation rates and 
insulin sensitivity in obese anovulatory women.38 Caloric restriction 
rather than specific macronutrient manipulation has been the key 
determinant of success.
The effect of metformin on weight loss has been controversial and it 
is currently not approved by the FDA for the treatment of obesity or 
for PCOS. However a few studies have demonstrated that metformin 
combined with lifestyle measures may be more effective in lowering 
weight than lifestyle and placebo alone.102
2.  Management metabolic risk factors 
Screening for diabetes and other cardiovascular risk factors (the 
metabolic syndrome) should be conducted in view of its prevalence 
in this population as discussed above. The management of glucose 
intolerance, dyslipidaemia and hypertension should follow current 
guidelines for these disorders. Patients should also be screened 
for sleep apnoea and referred for sleep studies when clinically 
indicated.
3.  Management of clinical hyperandrogenism
a. Oestrogen-containing oral contraceptives (OC)
All combined OC’s contain ethinyl oestradiol. Oestrogen suppresses 
LH and thus ovarian androgen production. Ethinyl oestradiol also 
increases hepatic synthesis of SHBG, thereby decreasing free 
testosterone levels. OC’s with low doses of cyproterone acetate or 
drospirenone (Diane-35® and Yasmin® respectively) are particularly 
effective in the treatment of hirsutism and acne because of their 
anti-androgenic properties (vide-infra), and because they attenuate 
the oestrogen-stimulated increase in SHBG to a far lesser extent 
than other progestogens.103 However some studies have reported 
the potentially adverse effects of oestrogen-containing OC’s 
on insulin resistance, dyslipidaemia, coagulability and vascular 
reactivity, and the long-term consequences of the OC in PCOS 
remain debateable.103-105 
b. Antiandrogens
All anti-androgens can cause pseudohermaphroditism of the 
male fetus and should therefore not be used without adequate 
contraception. 
i. Spironolactone is an aldosterone antagonist which competi-
tively inhibits the androgen receptor at higher doses, and 
inhibits 5α-reductase activity to a lesser extent. It is effective 
in improving hirsutism scores in 50% of patients with PCOS 
when used alone. Doses of 100–200 mg/d are recommended. 
A Cochrane review in 2003 found spironolactone 100 mg/
day to be superior to finasteride 5 mg/day and low dose 
cyproterone acetate 12.5 mg/day (first 10 days of cycle).106 
Oral contraceptives and spironolactone are synergistic and 
response rates can increase by 75% with the use of this 
combination.107 In a recent study, this combination was 
compared to flutamide alone and both were found to be 
equally effective in treating hirsutism.108
ii. Cyproterone acetate (CPA) is a progestogenic anti-androgen 
which competitively blocks the androgen receptor, inhibits 
5α-reductase activity and suppresses gonadotrophin and 
testosterone levels. It has a long half-life and doses of 
50–100 mg/d are usually administered from day 5 to 15 of 
the menstrual cycle (with or without ethinyl oestradiol [OC] 
from day 5 to 25 to maintain cyclicity). The dose can be 
1.  Abnormalities in the hypothalamic pituitary axis (HPA) and uncontrolled 
ovarian steroidogenesis
 These HPA abnormalities cause abnormal secretion of gonadotropin releasing 
hormone (GnRH) and LH, resulting in increased ovarian androgen production.
 LH stimulates the theca cell in ovary to synthesise androgens and FSH is 
responsible for the granulosa cell synthesising oestrogen via its actions 
on aromatase activity. Increased GnRH pulse frequency favours increased 
LH levels. Women with PCOS tend to have increased LH: FSH ratios. It is 
postulated that an increased GnRH frequency and low levels of progesterone 
(that normally decreases this pulsatility) from infrequent ovulation is the 
catalyst.93
2. Insulin resistance 
 Insulin drives increased androgen production from the ovary and adrenal and 
may alter gonadotrophin secretion.
 It is also thought to also be responsible for decreased SHBG synthesis in the 
liver thus increasing free testosterone in the circulation.
 In patients with PCOS, it has been revealed that there is selective tissue insulin 
sensitivity (skeletal muscle is resistant but ovary and adrenal are sensitive). 
Ovarian insulin sensitivity to the prevailing hyperinsulinaemia is thought to be 
one of the mechanisms that drive ovarian androgen production. Body mass 
index, hyperandrogenaemia and clinical hyperandrogenism are independent 
predictors of insulin resistance.94
3.  Ovarian follicular defect
 Women with PCOS have 2 to 6-fold more primary, secondary and small antral 
follicles when compared to normal ovaries.95 Abnormal androgen signalling 
is thought to be responsible for the increase in follicle number.96,97 It has also 
been postulated that follicles grow very slowly due to possibly deficient growth 
signals from the ovary.98
 There have been some studies showing a positive association between follicle 
number and androgen concentrations. 
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reduced to 5 mg/d after the maximal effect has been obtained. 
Diane 35® contains 2 mg CPA. Documented side effects of CPA 
include liver function abnormalities and a decreased libido. 
A recent review109 of anti-androgen studies demonstrated 
significant subjective improvements in hirsutism when CPA 
was combined with an oral contraceptive. However, there 
are no studies comparing CPA alone to a combination of 
CPA + OC. There are also no differences in CPA efficacy (for 
hirsutism) when compared to other anti-androgens even 
when differences in androgen levels are found.
iii. Flutamide is a non-steroidal pure anti-androgen which 
inhibits the androgen receptor in a dose-dependent manner. 
It has equal, if not better efficacy than spironolactone, CPA, 
finasteride and GnRH agonists in the treatment of hirsutism. 
The most frequently used dose in randomised trials is 
500 mg/d but some studies have suggested equal efficacy 
with 250 mg.109 Flutamide can also cause liver dysfunction, 
and may even result in liver failure and death. However 
hepatotoxicity has not been noted at doses up to 375 mg/d. 
It is not registered for the treatment of hirsutism and generally 
not recommended due to its association with liver failure.
iv. 5α-Reductase inhibitors: Finasteride: inhibits type 2 
5α-reductase and exerts its anti-androgenic effect by 
blocking the conversion of testosterone to biologically active 
dihydro-testosterone. However it does not specifically target 
the 5-alpha reductase found in the pilosebaceous unit (type1). 
The dose range is 2.5–7.5 mg/d. It’s efficacy in the treatment 
of hirsutism has been shown to be equivalent to, or slightly 
less than spironolactone and flutamide.110 Like flutamide, its 
use for the treatment of hirsutism is “off-label”. 
c)  Cosmetic measures: This is probably the most utilised way of 
treating hirsutism and is often combined with pharmacotherapy. 
i.  Laser electrolysis with topical eflornithine cream (Vaniqua®) is 
the most effective cosmetic measure for decreasing hair growth
ii.  Other depilatory measures are: waxing, shaving and bleaching
iii.  Minoxidil has been utilised in the treatment of androgenic 
alopecia
d)  Insulin sensitisers
Drugs that improve insulin resistance (metformin and 
thiazolidenediones) have been used to treat hirsutism as well. 
However metformin has limited success when compared to 
antiandrogens like spironolactone. A recent Cochrane review 
has shown that there was no difference between metformin and 
oral contraceptives in treating hirsutism.111 This has since been 
confirmed in a meta-analysis of patients with hirsutism (due to PCOS 
or idiopathic in nature), which also showed that metformin was 
inferior to both spironolactone and flutamide. In this meta-analysis, 
the effect of metformin on Ferriman-Gallwey scores was similar to 
placebo.112 Thus the clinical effectiveness of insulin-sensitisers for 
the treatment of hyperandrogenic symptoms remains to be proven.
Overall recommendations for the treatment of hirsutism
A reasonable approach would be to use spironolactone and 
topical eflornithine as a first-line treatment for hirsutism. A CPA 
or drospirenone-containing OC would be a reasonable choice for 
the patient who also has acne or demands menstrual cyclicity, 
particularly if they are not obese and have a low risk for venous 
thromboembolism. Finasteride should be reserved for patients 
who are unresponsive or intolerant of the above, and should be 
combined with an OC (because of fetal risk). Flutamide is no longer 
recommended for the treatment of hirsutism because of its liver 
toxicity, although some authors have found it to be particularly 
effective (vide supra) even at lower doses.
Metformin should not be used as monotherapy for hyperandrogenic 
symptoms, but should be added when other indications exist (IGT or 
diabetes), or it may be added to the OC in obese individuals (to offset 
the potential adverse metabolic consequences of the OC).
Combination treatments for hirsutism also appear to be promising 
as suggested by a meta-analysis which demonstrated that a 
combination of spironolactone or finasteride with an OC was more 
effective than monotherapy with an OC. Similarly, flutamide plus 
metformin was superior to metformin monotherapy.109
In terms of the clinical response to therapy, it should be noted that 
the more obese subjects show smaller responses to therapy, and 
that those with more severe hirsutism have a larger reduction in 
Ferriman-Gallwey scores.113
4. The management of menstrual dysfunction
The options for the treatment of irregular menstrual cycles 
and/or to prevent endometrial proliferation (caused by chronic 
unopposed oestrogen in PCOS), are to use a cyclic progestogen 
(e.g. medroxyprogesterone acetate 10mg from day 5 to 25) or 
a combined oral contraceptive pill. The ideal oral contraceptive 
remains elusive as there are no head to head trials for PCOS, but pills 
containing anti-androgenic progestins (ie. synthetic progestogens 
such as CPA and drospirenone) have the added advantage of improving 
acne and hirsutism. It has been argued that the monphasic OC may 
be preferred as it lends itself continuous use (ie. no placebo days 
thus allowing no reduction in oestradiol or SHBG levels, and no spike 
in gonadotrophins that could stimulate ovarian androgen synthesis). 
Theoretically the dose of ethinyl oestradiol should be in the range of 
30–35 µg so as to suppress ovarian follicular activity and stimulate 
hepatic SHBG synthesis. The risks of the oral contraceptives are its 
tendency for increased clotting events. In a patient with a strong 
personal or family history of clotting disorders a progestin only pill 
could be recommended. The latter is not recommended routinely 
because of unpredictable breakthrough bleeding.
Although metformin therapy has been associated with increased 
menstrual regularity it is not universally effective in this regard, and 
should therefore not be used as primary therapy for women wishing 
to menstruate regularly. Some authors do argue that it is better than 
the OC in that it poses no risk for dyslipidaemia and actually helps 
improve the metabolic profile.114 
5. The management of metabolic disturbances
It has already been noted that approximately half of the women 
with PCOS are obese and/or insulin resistant. Lifestyle modification 
remains the cornerstone for the management of the components 
of the metabolic syndrome. In obese PCOS individuals, weight 
loss is far more effective in improving insulin sensitivity than 
pharmacothaerapy.115 
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Metformin acts by decreasing the hepatic glucose output and it has 
some peripheral insulin sensitising properties. It decreases insulin 
levels, which potentially assists in minimising theca androgen 
production. However, its anti-androgen action is inferior to specific 
anti-androgen compounds. Metformin is being widely prescribed 
as a weight loss drug for PCOS. However, a 2003 meta-analysis of 
all metformin trials in PCOS demonstrated no net effect on weight 
loss.116 It has also been shown to improve some intermediate and 
surrogate markers of cardiovascular disease and risk.114 However 
the long-term significance of these findings remains uncertain. 
Metformin has a proven role for the prevention of type 2 diabetes in 
those with IGT, and in the management of type 2 diabetes. These two 
situations would constitute definite indications for metformin therapy 
in PCOS. When used in the absence of IGT and type 2 diabetes the 
target doses proposed have been variable ranging from 1500 mg–
2550 mg and there are no guidelines as to how long it could/should 
be used for. 
Thiozolidinediones increase insulin sensitivity in muscle, liver and 
adipose tissue. It also improves ovarian steroid biosynthesis and 
decreases insulin levels which assist in lowering hyperandrogenaemia. 
There have been some studies showing improved hypercoagulabilty 
markers as well.117 There is a concern regarding its use in pregnancy 
and thus is not used in women trying to conceive. Other negative 
effects are its association with weight gain, fluid retention and distal 
fractures in women. It has limited efficacy in improving hirsutism.117 
Its main role is as adjunctive therapy in patients with IGT or type 2 
diabetes when metformin is ineffective or not tolerated.
6. The management of infertility
The treatment of infertility associated with PCOS is beyond the 
scope of this article. Of note is the recent consensus on infertility 
treatment related to PCOS sponsored by the European Society of 
Human Reproduction and Embryology. The American Society for 
Reproductive Medicine has recommended clomiphene citrate as 
first line therapy for ovulation induction.118 A recent meta-analysis 
of metformin use for infertility in PCOS has shown that it improves 
ovulation but not pregnancy rates when compared to placebo except 
when it is used with clomiphene.119
Summary
PCOS is a common condition that incorporates oligoanovulation and 
evidence of hyperandrogenism. Recent consensus guidelines have 
now included polycystic ovarian morphology as a diagnostic criterion. 
Androgen excess and insulin resistance are currently recognised 
to be responsible for much of the phenotypic presentation, though 
insulin resistance is far from universally present. The approach 
to managing these patients involves addressing the patient’s 
dominant symptom as well as the metabolic consequences of the 
disease. Lifestyle modification has benefits that are synergistic with 
pharmacological therapies that improve hyperandrogenism and 
improve insulin sensitivity thus assisting in regulating menstrual 
cycles and increasing fertility and preventing potential adverse 
metabolic and cardiovascular consequences. Measurement of 
insulin levels for diagnosis, prognosis and monitoring are mythical, 
as is the notion that metformin is the panacea for obese women with 
this disorder.
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